TRAMETINIB
Manufacturer: Novartis Pharmaceuticals Corporation
Score: 141.0
Mekinist (Trametinib) is a kinase inhibitor used for the treatment of various cancers, including melanoma, non-small cell lung cancer (NSCLC), and anaplastic thyroid cancer (ATC), in patients with specific genetic mutations. It is often used in combination with dabrafenib. Key clinical findings indicate its efficacy in improving survival rates and reducing tumor growth in these patient populations. Important safety information includes warnings about potential fetal harm, cardiomyopathy, and ocular toxicities. The main dosing recommendations vary based on the condition being treated and the patient's age and weight. Special population considerations include use during pregnancy, nursing mothers, pediatric use, and geriatric use, each with specific guidelines and precautions.
Mekinist can cause fetal harm when administered to a pregnant woman and has warnings regarding cardiomyopathy, ocular toxicities, and other serious adverse reactions
Dose reductions for adverse reactions associated with MEKINIST are presented in Tables 3 and 4
2 mg orally once daily
Based on body weight (Table 1)
2 mg orally once daily
Not established
2 mg orally once daily
Not established